These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38564684)
1. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. Perez JK; Kleber J; Rothe M; Mangat P; Garrett-Mayer E; Schilsky RL JCO Precis Oncol; 2024 Mar; 8():e2300615. PubMed ID: 38564684 [TBL] [Abstract][Full Text] [Related]
2. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations. Koopman B; Groen HJM; Ligtenberg MJL; Grünberg K; Monkhorst K; de Langen AJ; Boelens MC; Paats MS; von der Thüsen JH; Dinjens WNM; Solleveld N; van Wezel T; Gelderblom H; Hendriks LE; Speel EM; Theunissen TE; Kroeze LI; Mehra N; Piet B; van der Wekken AJ; Ter Elst A; Timens W; Willems SM; Meijers RWJ; de Leng WWJ; van Lindert ASR; Radonic T; Hashemi SMS; Heideman DAM; Schuuring E; van Kempen LC Oncologist; 2021 Aug; 26(8):e1347-e1358. PubMed ID: 33111480 [TBL] [Abstract][Full Text] [Related]
3. Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India. Mathew A; Davis S; Boby JM; R I A; Suryavanshi M; Dawood SS; Panda PK; Nag SM; Das A; Rohatgi N; Popat S; Shah RNH; Thampy C; Parikh AR; Yadav S; Mehta P; Singh R; Mukherji D; Shilpakar R; Mullapally SK; Sirohi B JCO Glob Oncol; 2024 Mar; 10():e2300330. PubMed ID: 38484196 [TBL] [Abstract][Full Text] [Related]
4. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan. Naito Y; Sunami K; Kage H; Komine K; Amano T; Imai M; Koyama T; Ennishi D; Kanai M; Kenmotsu H; Maeda T; Morita S; Sakai D; Watanabe K; Shirota H; Kinoshita I; Yoshioka M; Mamesaya N; Ito M; Kohsaka S; Saigusa Y; Yamamoto K; Hirata M; Tsuchihara K; Yoshino T JAMA Netw Open; 2022 Dec; 5(12):e2245081. PubMed ID: 36469316 [TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
6. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center. Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736 [TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review. Larson KL; Huang B; Weiss HL; Hull P; Westgate PM; Miller RW; Arnold SM; Kolesar JM JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34632252 [TBL] [Abstract][Full Text] [Related]
8. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer. Ciliberto G; Canfora M; Terrenato I; Agnoletto C; Agustoni F; Amoroso L; Baldassarre G; Curigliano G; Delmonte A; De Luca A; Fiorentino M; Gregorc V; Ibrahim T; Lazzari C; Mastronuzzi A; Pronzato P; Santoro A; Scambia G; Tommasi S; Vingiani A; Giacomini P; De Maria R J Exp Clin Cancer Res; 2022 Oct; 41(1):305. PubMed ID: 36245005 [TBL] [Abstract][Full Text] [Related]
9. Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards. Rieke DT; de Bortoli T; Horak P; Lamping M; Benary M; Jelas I; Rüter G; Berger J; Zettwitz M; Kagelmann N; Kind A; Fabian F; Beule D; Glimm H; Brors B; Stenzinger A; Fröhling S; Keilholz U BMC Med; 2022 Oct; 20(1):367. PubMed ID: 36274133 [TBL] [Abstract][Full Text] [Related]
10. Molecular Tumor Boards in Clinical Practice. Luchini C; Lawlor RT; Milella M; Scarpa A Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959 [TBL] [Abstract][Full Text] [Related]
11. Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance. Walters MK; Ackerman AT; Weese JL; Ruggeri A; Mullane MP; Hunt A; Wilson A; Ramczyk BL; Thompson MA JCO Precis Oncol; 2022 Oct; 6():e2200132. PubMed ID: 36265115 [TBL] [Abstract][Full Text] [Related]
12. Implementation and Outcomes of a Molecular Tumor Board at Herbert-Herman Cancer Center, Sparrow Hospital. Trivedi H; Acharya D; Chamarthy U; Meunier J; Ali-Ahmad H; Hamdan M; Herman J; Srkalovic G Acta Med Acad; 2019 Apr; 48(1):105-115. PubMed ID: 31264438 [TBL] [Abstract][Full Text] [Related]
17. A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence. Sunami K; Naito Y; Saigusa Y; Amano T; Ennishi D; Imai M; Kage H; Kanai M; Kenmotsu H; Komine K; Koyama T; Maeda T; Morita S; Sakai D; Hirata M; Ito M; Kozuki T; Sakashita H; Horinouchi H; Okuma Y; Takashima A; Kubo T; Hironaka S; Segawa Y; Yakushijin Y; Bando H; Makiyama A; Suzuki T; Kinoshita I; Kohsaka S; Ohe Y; Ishioka C; Yamamoto K; Tsuchihara K; Yoshino T JAMA Oncol; 2024 Jan; 10(1):95-102. PubMed ID: 38032680 [TBL] [Abstract][Full Text] [Related]
18. The molecular tumor board: a tool for the governance of precision oncology in the real world. Incorvaia L; Russo A; Cinieri S Tumori; 2022 Aug; 108(4):288-290. PubMed ID: 34918610 [TBL] [Abstract][Full Text] [Related]
19. Molecular Tumor Boards: current practice and future needs. van der Velden DL; van Herpen CML; van Laarhoven HWM; Smit EF; Groen HJM; Willems SM; Nederlof PM; Langenberg MHG; Cuppen E; Sleijfer S; Steeghs N; Voest EE Ann Oncol; 2017 Dec; 28(12):3070-3075. PubMed ID: 29045504 [TBL] [Abstract][Full Text] [Related]